When will immunomodulation for the prevention of type 1 diabetes be a reality?

Diabetic Medicine, Supplement

Volumn 20, Issue 1, 2003, Pages 10-13

  Leech, N J ^a  

^a Newcastle Diabetes Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; INSULIN; MONOCLONAL ANTIBODY CD3; ANTIGEN;

B LYMPHOCYTE; CELL FUNCTION; FOLLOW UP; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NOTE; VACCINATION; ANIMAL; ARTICLE; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MOUSE; NONOBESE DIABETIC MOUSE; PRIMARY PREVENTION;

ANIMALS; ANTIGENS; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED NOD; PRIMARY PREVENTION;

EID: 28244484021     PISSN: 14665468     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (16)

1. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen I. β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double blind, phase II trial. Lancet 2001; 358: 1749-1753.
2. Chaillous L, Lefèvre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C et al. Oral insulin administration and residual β-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Lancet 2000; 356: 545-549.
3. Diabetes prevention trial-Diabetes Study group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002; 346: 1685-1691.
4. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346: 1692-1698.
5. Wells H. Studies on the chemistry of anaphylaxis III. Experiments with isolated proteins, especially those of hen's egg. J Infect Dis 2002; 9: 147-151.
6. Weiner HL. Oral tolerance for the treatment of autoimmune disease. Annu Rev Med 2002; 48: 341-351.
7. Allen H, Klingensmith GJ, Jensen P, Simoes E, Hayward A, Chase HP. Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. Diabetes Care 2002; 22: 1703-1707.
8. Canadian-European Randomized Control Trial Group. Cyclosporin induced remission of IDDM after early intervention: association with enhanced insulin secretion. Diabetes 1998; 37: 1574-1582.
9. Carel JC, Boitard C, Eisenbarth G, Bach JF, Bougneres PF. Cyclosporine delays but does not prevent clinical onset in glucose intolerant pretype 1 diabetic children. J Autoimmun 1996; 9: 739-745.
10. Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P et al. Cyclosporin increases the rate and length of remission in insulin dependent diabetes of recent onset. Lancet 1986; ii: 119-123.
11. Genain CP, Abel K, Belmar N, Villinger F, Rosenberg DP, Linington C et al. Late complications of immune deviation therapy in a nonhuman primate. Science 1996; 274: 2054-2057.
12. Elias D, Cohen I. Treatment of autoimmune diabetes and insulitis in NOD mice with heat-shock-protein-60 peptide p277. Diabetes 1995; 44: 1132-1138.
13. Zhang ZJ, Davidson L, Eisenbarth GS, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 1991; 88: 10252-10256.
14. Palmer JP. Manipulating the Type 1 diabetes disease process, man versus mouse. Diabetes Care 2002; 25: 1240-1241.
15. Fuchtensbusch M, Rabl W, Grassle B, Bachmann W, Standl E, Ziegler AG. Delay in type 1 diabetes in high risk, first degree relatives by parenteral insulin administration: the Schwabing insulin prophylaxis trial. Diabetologia 1998; 41: 536-541.
16. Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type 1 diabetes. Lancet 1993; 341: 927-928.